Back to top
more

Quotient Limited (QTNT)

(Delayed Data from NSDQ)

$9.25 USD

9.25
348,584

+0.28 (3.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $9.25 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nemaura Medical, Inc. (NMRD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 0% and 75.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Inc. (MASS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

908 Devices Inc. (MASS) delivered earnings and revenue surprises of 9.09% and 0.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Paragon 28, Inc. (FNA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of 0% and 8.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 21.43% and 9.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 32.26% and 9.98%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Quotient (QTNT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Quotient (QTNT) delivered earnings and revenue surprises of -32.14% and 6.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Quotient (QTNT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quotient (QTNT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quotient (QTNT) delivered earnings and revenue surprises of 26.47% and 23.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quotient (QTNT) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Quotient (QTNT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks.com featured highlights include: SunOpta, Lazydays, Quotient, OptiNose and Motorcar Parts of America

by Zacks Equity Research

Zacks.com featured highlights include: SunOpta, Lazydays, Quotient, OptiNose and Motorcar Parts of America

Sanghamitra Saha headshot

Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Quotient (QTNT) Could Find Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Quotient (QTNT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Is the Options Market Predicting a Spike in Quotient Limited (QTNT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Quotient Limited (QTNT) stock based on the movements in the options market lately.

Quotient (QTNT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quotient (QTNT) delivered earnings and revenue surprises of 0.00% and 14.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Quotient (QTNT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Quotient (QTNT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Quotient (QTNT) stock based on the movements in the options market lately.

Quotient (QTNT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Quotient (QTNT) delivered earnings and revenue surprises of 7.69% and -0.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for June 29th

by Zacks Equity Research

ITRG, TARA, QTNT, VNCE and APDN have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2021.